Work

The efficacy of cyclophosphamide in the treatment of Kawasaki disease complicated with coronary artery aneurysms in children: insights from a single-center experience

Year: 2026
Type: article
Abstract: Objective Giant coronary artery aneurysms (g-CAA) are the most dangerous complications for children with Kawasaki disease (KD). Before 2025, once the fever subsides, there are no treatment recommendations for preventing the progression of CAA. This study aims to evaluate CAA outcomes over 2 years in children with KD complicated by CAA treated with intravenous and/or oral cyclophosphamide (CTX), compared with conventional therapy alone. Methods A total of 41 children with KD along with at least one CAA ≥4 mm or Z score ≥5 were enrolled. All patients were diagnosed and treated at the Department of Pediatric Cardiology, Shengjing Hospital Affiliated to China Medical University, between March 2012 and September 2026, with a follow-up duration of at least 2 years. 21 patients receiving conventional therapy served as the control group (Ctrl). From February 2021 onward, 20 children with midgrade or giant CAA received additional CTX therapy and were assigned to the CTX group (CTX-G). CTX treatment included a single intravenous dose (2 mg/kg) and/or oral CTX initiated within 4 months of disease onset (1.5 mg/kg/day for 3 months, followed by a 2-month break as one treatment cycle). The mean initiation time for oral CTX was 2.4 months after disease onset, with an average treatment duration of 4.4 months. Results Improvement was observed in 2 infants with CAA ≥8 mm in RCA, with diameters decreasing from 8.5 mm (Z = 20.71) and 9.1 mm (Z = 20.08) to 6.3 mm (Z = 10.4) and 4.4 mm (Z = 5.67), respectively. In patients with CAA ≥4 mm and <8 mm with Z ≥10, baseline coronary dimensions and Z scores of the LAD and RCA did not differ between groups (P > 0.05). After 2 years, both the inner diameter and Z score of the RCA in CTX-G were significantly smaller than those in Ctrl (P < 0.05). Conclusion CAA ≥8 mm involving the RCA in young patients may demonstrate partial regression. For patients with CAA ≥4 mm and <8 mm with Z ≥10, early CTX treatment may effectively limit further aneurysm progression, particularly in the RCA.
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7236043313
FWCI:
Cites: 28
Cited by:
Related to: 10